Trending Articles

article thumbnail

Optimising T-cell expansion to improve early-stage cell therapy

Drug Target Review

Maria Knaub, Senior Medical Affairs Operations Lead at Terumo Blood and Cell Technologies (Terumo BCT), brings a unique blend of frontline experience and scientific expertise to the fore of cell therapy innovation. Her background as a paramedic and PhD in cancer biology have led Maria to lead global medical affairs efforts focused on advancing cell and gene therapies (CGTs).

article thumbnail

This AI-powered lab runs itself—and discovers new materials 10x faster

Science Daily: Pharmacology News

A new leap in lab automation is shaking up how scientists discover materials. By switching from slow, traditional methods to real-time, dynamic chemical experiments, researchers have created a self-driving lab that collects 10 times more data, drastically accelerating progress. This new system not only saves time and resources but also paves the way for faster breakthroughs in clean energy, electronics, and sustainability—bringing us closer to a future where lab discoveries happen in days, not y

Research 270
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Researchers grow 400+ brain cell types—a leap for Alzheimer’s and Parkinson’s research

Science Daily: Pharmacology News

Scientists at ETH Zurich have broken new ground by generating over 400 types of nerve cells from stem cells in the lab, far surpassing previous efforts that produced only a few dozen. By systematically experimenting with combinations of morphogens and gene regulators, the researchers replicated the vast diversity of neurons found in the human brain.

Research 261
article thumbnail

Multifaceted In Silico Screening Strategies Identifies Potent Inhibitors Facilitating Inhibition of ZNF726 Activity in Breast Cancer

Chemical Biology and Drug Design

Zoledronic acid was identified as a lead hit targeting ZNF726 activity, inhibiting its proliferative effects on breast cancer cells. Zoledronic acid inhibits cellular cholesterol level through the inhibition of ZNF726 activity in breast cancer cells. Nine phytochemicals were identified from docking studies that might be used as potential therapeutics for targeting ZNF726 activity.

Treatment 100
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Transforming Cancer Therapy: Insights from 2025 H1 FDA Approvals and Preclinical Drug Discovery

Crown Bioscience

Oncology drug approvals in H1 2025 In the first half of 2025, the FDA’s Center for Drug Evaluation and Research (CDER) approved a total of 16 novel drugs , with half of these drugs related to the treatment of cancer. Both the novel and supplemental oncology approvals reflected recent developmental innovations, including an increased focus on targeted, immunologically driven, and personalized oncology therapies, targeting a broad range of cancers.

article thumbnail

Recap Of The Collaborative Drug Discovery's Inaugural Canadian User Group Meeting

Collaborative Drug

The 2025 CDD User Group Meeting (UGM) Canada brought together researchers, industry experts, and thought leaders to discuss the latest advancements in drug discovery, data management, and collaborative research.

Drugs 130

More Trending

article thumbnail

NGS is evolving: collaboration and tech lead the way

Drug Target Review

The next-generation sequencing (NGS) market is experiencing rapid growth, which is expected to continue for the foreseeable future. Research by Markets and Markets projects the market to grow from $12.13 billion in 2023 to about $23.55 billion by 2029, a compound annual growth rate (CAGR) of approximately 13.2 percent.​ 1 Emergen Research attributes this to the advantages of high-throughput sequencing technologies and declining sequencing costs​. 2 This trend reflects the increasing demand for g

RNA 92
article thumbnail

Some Newer Antiseizure Meds Safer During Pregnancy

Drugs.com

THURSDAY, July 17, 2025 — Some newer antiseizure medications appear to be safer for pregnant women to take without risk of birth defects, a new study says. Second-generation antiseizure drugs like levetiracetam, oxcarbazepine, gabapentin and.

Drugs 283
article thumbnail

Case study: an Open Targets Platform MCP server

The Open Targets Blog

This blog post is part of a series that will explore applications and expansions of the Open Targets informatics ecosystem, particularly the Open Targets Platform , through conversations with our users. Nick Ren is an engineer with a lot of experience working alongside geneticists. In 2019, as part of David Goldstein’s group, he created ATAV , a population-scale genomic-analysis platform aiming to speed up gene discovery and improve care for patients at Columbia University Medical Center.

article thumbnail

CRISPR uncovers gene that supercharges vitamin D—and stops tumors in their tracks

Science Daily: Pharmacology News

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their survival but also disrupted thousands of other genes tied to cancer and metabolism. This opens the door to highly targeted cancer therapies—by either cutting off vitamin D supply to tumors or enhancing the gene’s activity to boost health.

Therapies 226
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

"Designer Drugs" in the 21st Century

Common Sense for Drug Policy Blog

"Designer Drugs" in the 21st Century "The term “designer drugs” was originally introduced to describe novel substances that are derived from clandestine alterations of well-known drugs of abuse, preserving or enhancing pharmacologic effects while remaining outside of legal control (Jerrard 1990 ). The term is currently applied more widely to include substances that originate from industrial or academic research but never receive medical approval.

Drugs 52
article thumbnail

Outsmarting immune suppression through GPCR innovation

Drug Target Review

Immuno-oncology has transformed cancer treatment, but for many patients, tumours remain resistant to even the most advanced immune checkpoint inhibitors. Domain Therapeutics is addressing this challenge by focusing on G protein-coupled receptors (GPCRs) – a well-validated and the largest family of drug targets that remains underexplored in cancer and inflammation.

article thumbnail

Risevistinel

New Drug Approvals

Risevistinel NYX-783 CAS 2591344-26-0 , UNII-52TU5MZG22 NYX 2925, 2012536-16-0, X062KF5ZV3 C 14 H 23 N 3 O 4 , 297.35 UNII-52TU5MZG22, X062KF5ZV3 (αS,4R)-α-[(1R)-1-Hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-2,5-diazaspiro[3.4]octane-2-acetamide 2,5-Diazaspiro[3.4]octane-2-acetamide, α-[(1 R )-1-hydroxyethyl]-5-(2-methyl-1-oxopropyl)-1-oxo-, (α S ,4 S )- (2 S ,3 R )-3-hydroxy-2-[(4 S )-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide NYX-783, NYX 2925 CS-0113907 HY-135741 NY

Disease 62
article thumbnail

Winning Regulatory Trust: Six Smart Strategies for Emerging Biotechs

PPD

Effective communication with regulatory authorities is critical for small biotech companies, as it is often the key to success in clinical trials. When small and emerging companies are able to build strong, trust-based relationships with regulators, they often see benefits like reduced development risk and accelerated timelines. However, to achieve these benefits, sponsors must have experience in and knowledge of the regulatory landscape.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

One shot, seven days: Long-acting levodopa gel tackles Parkinson’s tremors

Science Daily: Pharmacology News

Researchers in Australia have created a biodegradable gel that delivers Parkinson’s medications through a single weekly shot, replacing the need for multiple daily pills. Injected just under the skin, the gel steadily releases levodopa and carbidopa for seven days, helping keep tremors and stiffness in check while easing side effects linked to fluctuating doses.

Research 225
article thumbnail

Challenges and Solutions to Drug-Drug Interactions for Clinical Development

DrugBank

Drug-drug interactions (DDI) are a significant concern in clinical trials, where the safe and effective administration of drugs to patients is crucial. These interactions can alter the pharmacological activity of one or more drugs, potentially leading to diminished therapeutic effects or unexpected toxic reactions. The complexity of pharmacokinetics and pharmacodynamics, coupled with the variability in patient populations, makes predicting and managing DDI a particularly challenging aspect of dr

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 1

Drug Target Review

The pharmaceutical industry faces a persistent challenge: despite significant investments in drug development, a substantial proportion of promising candidates fail due to unforeseen toxicity issues. In a recent conversation with Layla Hosseini-Gerami, Chief Data Science Officer and Co-founder of Ignota Labs , we explored this critical issue, considering how artificial intelligence (AI) and advanced data science approaches may provide solutions.

Drugs 65
article thumbnail

Rezatapopt

New Drug Approvals

Rezatapopt, PC 14586 CAS 2636846-41-6 Molecular Weight 545.57 Synonyms PC14586 Formula C 28 H 31 F 4 N 5 O 2 CAS No. 2636846-41-6 4-[3-[4-[[(3 S ,4 R )-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy- N -methylbenzamide 4-[3-[4-[[(3S,4R)-3-fluoro-1-methylpiperidin-4-yl]amino]-1-(2,2,2-trifluoroethyl)indol-2-yl]prop-2-ynylamino]-3-methoxy-N-methylbenzamide Benzamide, 4-[[3-[4-[[(3S,4R)-3-fluoro-1-methyl-4-piperidinyl]amino]-1-(2,2,2-trifluoroe

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron

Alta Sciences

Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron aasimakopoulos Tue, 07/22/2025 - 18:05 We were thrilled to represent Altasciences at this year’s American Society for Mass Spectrometry (ASMS) conference in Baltimore. With 6,000 scientists, students, and industry professionals from around the globe in attendance, it was an excellent opportunity to learn about the latest developments in mass spectrometry and share insights

article thumbnail

Chirality shock: Geneva chemists forge millennia-stable ‘mirror-proof’ drugs

Science Daily: Pharmacology News

Chemists at the University of Geneva and University of Pisa have crafted a novel family of chiral molecules whose mirror-image “handedness” remains rock-solid for tens of thousands of years. By swapping the usual carbon-bound arms for oxygen and nitrogen, they introduced an unprecedented stereogenic center and proved its extreme resilience through dynamic chromatography and quantum calculations.

Drugs 132
article thumbnail

ICH E6(R3) Guidance: Why Clinical Trial Teams Need More Than Just a Process Update

Quanticate

This article is based on the final, Step 4 version of the ICH E6(R3) Good Clinical Practice guidance, officially adopted on 6 January 2025 by the International Council for Harmonisation. This Step 4 document is the version recommended for regulatory adoption across all ICH member regions.

article thumbnail

New Pyrazole‐Based Tetrazole Derivatives: Synthesis, Characterization, and Their Vasorelaxant and α‐Amylase Inhibition Activities

Chemical Biology and Drug Design

A family of hybrid pyrazole tatrazole compounds was synthesized and characterized. They show a good vasorelaxant and a-amylase inhibition activities. ABSTRACT A series of new linear pyrazole-based tetrazole derivatives 1 – 10 were synthesized and characterized. The structures of the intermediate compounds were confirmed using 1 H and 13 C NMR spectroscopy, as well as high-resolution mass spectrometry (HRMS).

Research 100
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

Drug Channels

Is the gross-to-net bubble —the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year. Yet despite this record total, the bubble expanded at the slowest rate in at least a decade.

article thumbnail

GLP-1 Drugs Increase Risk Of Acid Reflux, GERD

Drugs.com

TUESDAY, July 15, 2025 — Folks using GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, a new study says. People with type 2 diabetes were more likely to suffer from gastroesophageal reflux disease (GERD).

Drugs 297
article thumbnail

Scientists just found 200+ hidden proteins that may drive Alzheimer’s

Science Daily: Pharmacology News

A surprising new study has uncovered over 200 misfolded proteins in the brains of aging rats with cognitive decline, beyond the infamous amyloid and tau plaques long blamed for Alzheimer’s. These shape-shifting proteins don’t clump into visible plaques, making them harder to detect but potentially just as harmful. Scientists believe these “stealth” molecules could evade the brain’s cleanup systems and quietly impair memory and brain function.

Treatment 214
article thumbnail

How Causal Inference is Transforming Real-World Observational Prospective Trials

Quanticate

Learn how causal inference methods improve real-world observational trials by reducing bias, enhancing validity, and informing decisions.

Trials 52
article thumbnail

Resigratinib

New Drug Approvals

Resigratinib, KIN 3248 CAS 2750709-91-0 C 26 H 27 F 2 N 7 O 3 523.5 g/mol 3-[2-(1-cyclopropyl-4,6-difluorobenzimidazol-5-yl)ethynyl]-1-[(3 S ,5 R )-5-(methoxymethyl)-1-prop-2-enoylpyrrolidin-3-yl]-5-(methylamino)pyrazole-4-carboxamide 3-[2-(1-Cyclopropyl-4,6-difluoro-1H-benzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]-5-(methylamino)-1H-pyrazole-4-carboxamide 3-[2-(1-cyclopropyl-4,6-difluorobenzimidazol-5-yl)ethynyl]-1-[(3S,5R)-5-(methoxymethyl)-1-p

article thumbnail

FDA rejects Ultragenyx gene therapy over manufacturing concerns

BioPharma Drive: Drug Pricing

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather than a roadblock.

Therapies 152
article thumbnail

CMC Expectations During Drug Substance Transfer from Ex-US Manufacturers

thought leadership

Regulatory Drivers for US-based API Manufacturers Recent shifts in US tariff policies have introduced new pressure points in the global pharmaceutical supply chain, particularly for manufacturers sourcing drug substances and active pharmaceutical ingredients (APIs) from overseas—most notably from China. In response, many firms are now evaluating the feasibility of transferring manufacturing operations to US facilities.

article thumbnail

This flat chip uses twisted light to reveal hidden images

Science Daily: Pharmacology News

Using advanced metasurfaces, researchers can now twist light to uncover hidden images and detect molecular handedness, potentially revolutionizing data encryption, biosensing, and drug safety.

Research 198
article thumbnail

How Agentic AI is Reshaping Marketing and CX Operations

Perficient: Drug Development

As Generative AI (GenAI) continues to evolve, its promise of speed and scale is capturing the attention of senior executives across industries. According to Adobe’s 2025 Digital Trends Report , 86% of leaders expect GenAI to significantly increase content production both in speed and volume. But for the marketing and customer experience (CX) teams tasked with implementing these tools, the reality is more nuanced.

article thumbnail

AI Meets Drug Discovery – But Who Gets the Patent?

Drug Patent Watch

"The Patent Paradox: As AI Revolutionizes Drug Discovery, Who Owns the Breakthroughs? The pharmaceutical industry is on the cusp of a revolution, with artificial intelligence (AI) poised to transform the way new medicines are discovered. But as AI-powered tools begin to yield groundbreaking results, a pressing question arises: who will hold the patent rights to these innovations?

Drugs 53